April 18, 2018 / 11:25 PM / 5 months ago

BRIEF-Roche Expands Indication For Cobas EGFR Mutation Test V2 As Companion Diagnostic With Tagrisso

April 19 (Reuters) - Roche Holding AG:

* ROCHE EXPANDS INDICATION FOR COBAS® EGFR MUTATION TEST V2 AS A COMPANION DIAGNOSTIC WITH TAGRISSO®

* ROCHE HOLDING- NEW INDICATION AS COMPANION DIAGNOSTIC WITH ASTRAZENECA’S TAGRISSO IN FIRST LINE TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

* ROCHE -RECEIVED APPROVAL FROM FDA OF ITS PMA SUPPLEMENT FOR COBAS EGFR MUTATION TEST V2 TO BE USED AS COMPANION DIAGNOSTIC TEST WITH TAGRISSO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below